Paula
Rodríguez Otero
Consultora Médica
Centro de Investigación Médica Aplicada
Pamplona, EspañaPublicacions en col·laboració amb investigadors/es de Centro de Investigación Médica Aplicada (43)
2024
-
A CD38/CD3xCD28 trispecific T-cell engager as a potentially active agent in multiple myeloma patients relapsed and/or refractory to anti-CD38 monoclonal antibodies
British Journal of Haematology
-
Belantamab mafodotin: an important treatment option for vulnerable patients with triple class exposed relapsed and/or refractory multiple myeloma
Haematologica
-
Biomarkers of Efficacy and Safety of the Academic BCMA-CART ARI0002h for the Treatment of Refractory Multiple Myeloma
Clinical Cancer Research, Vol. 30, Núm. 10, pp. 2085-2096
-
Immune dysfunction prior to and during vaccination in multiple myeloma: a case study based on COVID-19
Blood Cancer Journal, Vol. 14, Núm. 1
-
Impact of treatment effect on MRD and PFS: an aggregate data analysis from randomized clinical trials in multiple myeloma
Blood Advances
-
Serum mass spectrometry for treatment monitoring in patients with multiple myeloma receiving ARI0002h CAR T-cells
British Journal of Haematology
-
The genomic profiling of high-risk smoldering myeloma patients treated with an intensive strategy unveils potential markers of resistance and progression
Blood cancer journal, Vol. 14, Núm. 1, pp. 74
2023
-
Cobimetinib Alone and Plus Venetoclax With/Without Atezolizumab in Patients With Relapsed/Refractory Multiple Myeloma
Clinical Lymphoma, Myeloma and Leukemia, Vol. 23, Núm. 1, pp. e59-e70
-
Definition and Clinical Significance of the Monoclonal Gammopathy of Undetermined Significance-Like Phenotype in Patients With Monoclonal Gammopathies
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 41, Núm. 16, pp. 3019-3031
-
Efficacy and safety of cilta-cel in patients with progressive multiple myeloma after exposure to other BCMA-targeting agents
Blood, Vol. 141, Núm. 3, pp. 219-230
-
Fractionated initial infusion and booster dose of ARI0002h, a humanised, BCMA-directed CAR T-cell therapy, for patients with relapsed or refractory multiple myeloma (CARTBCMA-HCB-01): a single-arm, multicentre, academic pilot study
The Lancet Oncology, Vol. 24, Núm. 8, pp. 913-924
-
Phase 1b Study of Isatuximab in Combination With Bortezomib, Cyclophosphamide, and Dexamethasone in Newly Diagnosed, Transplant-ineligible Multiple Myeloma Patients
HemaSphere
-
Preclinical models for prediction of immunotherapy outcomes and immune evasion mechanisms in genetically heterogeneous multiple myeloma
Nature Medicine, Vol. 29, Núm. 3, pp. 632-645
-
Prevention and management of adverse events during treatment with bispecific antibodies and CAR T cells in multiple myeloma: a consensus report of the European Myeloma Network
The Lancet Oncology, Vol. 24, Núm. 6, pp. e255-e269
-
Single-agent belantamab mafodotin in patients with relapsed or refractory multiple myeloma
The Lancet Haematology
2022
-
CAR density influences antitumoral efficacy of BCMA CAR T cells and correlates with clinical outcome
Science Advances, Vol. 8, Núm. 39
-
Cellular therapy for multiple myeloma: what's now and what's next
Hematology. American Society of Hematology. Education Program, Vol. 2022, Núm. 1, pp. 180-189
-
Circulating Tumor Cells for the Staging of Patients With Newly Diagnosed Transplant-Eligible Multiple Myeloma
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 40, Núm. 27, pp. 3151-3161
-
Iberdomide with dexamethasone: a new backbone for myeloma treatment?
The Lancet. Haematology
-
Landscape and clinical significance of long noncoding RNAs involved in multiple myeloma expressed fusion transcripts
American Journal of Hematology